Doximity Inc (DOCS)
Official siteHEALTHCARE • HEALTH INFORMATION SERVICES • NYSE
Market Cap: $5.95B
Last updated: Nov 17, 2026 at 11:03 AM ET
Doximity Inc (DOCS) Financials: Revenue, Profit and Cash Flow
Doximity reported revenue of $644.86M for the fiscal year ended Mar 31, 2026, up 13.1% from the year before. That year, net income was $196.05M with a net margin of 30.4%, operating cash flow was $326.46M and free cash flow was $317.56M. The quarter ended Sep 30, 2026 had revenue of $174.54M and net income of $34.73M.
Revenue and Margins
The operating margin was 33.3% in the fiscal year ended Mar 2026. Over the 7 years to Mar 2026, revenue grew from $85.69M, a compound annual rate of 33.4%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Mar 2026 | $644.86M | +13.1% | 89.1% | 33.3% | 30.4% |
| Mar 2025 | $570.40M | +20.0% | 90.2% | 39.9% | 39.1% |
| Mar 2024 | $475.42M | +13.5% | 89.3% | 34.5% | 31.0% |
| Mar 2023 | $419.05M | +22.0% | 87.2% | 29.9% | 26.9% |
| Mar 2022 | $343.55M | +66.0% | 88.4% | 33.0% | 45.1% |
| Mar 2021 | $206.90M | +77.8% | 84.9% | 25.8% | 24.3% |
| Mar 2020 | $116.39M | +35.8% | 87.2% | 19.0% | 25.5% |
| Mar 2019 | $85.69M | N/A | 87.3% | 8.1% | 9.1% |
Income Statement
In the fiscal year ended Mar 2026, net income fell 12.2% from the year before. In the quarter ended Sep 2026, net income fell 44.0% from the same quarter a year earlier.
Annual
| Line item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $644.86M | $570.40M | $475.42M | $419.05M | $343.55M | $206.90M | $116.39M | $85.69M |
| Cost of revenue | $70.33M | $55.87M | $50.67M | $53.49M | $39.79M | $31.20M | $14.90M | $10.89M |
| Gross profit | $574.54M | $514.52M | $424.75M | $365.56M | $303.76M | $175.70M | $101.49M | $74.81M |
| Research and development | $130.70M | $93.04M | $81.98M | $80.19M | $62.35M | $43.87M | $32.44M | $27.50M |
| Operating income | $214.92M | $227.80M | $163.88M | $125.11M | $113.54M | $53.30M | $22.16M | $6.92M |
| Net income | $196.05M | $223.19M | $147.58M | $112.82M | $154.78M | $50.21M | $29.74M | $7.83M |
| EBITDA | $235.20M | $236.77M | $177.78M | $155.34M | $133.13M | $68.55M | $29.04M | $7.47M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $174.54M | $156.62M | $145.37M | $185.05M | $168.53M | $145.91M | $138.29M | $168.60M | $136.83M | $126.68M | $118.06M | $135.28M |
| Gross profit | $149.19M | $132.93M | $125.97M | $166.35M | $152.10M | $130.12M | $123.82M | $154.42M | $123.16M | $113.13M | $105.49M | $123.09M |
| Operating income | $43.92M | $33.64M | $24.83M | $71.90M | $63.68M | $54.52M | $48.68M | $79.92M | $53.14M | $46.05M | $41.85M | $58.55M |
| Net income | $34.73M | $24.32M | $19.11M | $61.56M | $62.06M | $53.32M | $62.46M | $75.20M | $44.15M | $41.38M | $40.62M | $47.96M |
Balance Sheet
As of Mar 2026, cash and equivalents exceeded short-term debt of $2.11M by $217.07M.
Annual
| Line item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $1.12B | $1.26B | $1.08B | $1.14B | $991.36M | $251.72M | $138.92M | $86.56M |
| Current assets | $944.26M | $1.09B | $912.94M | $975.45M | $904.14M | $209.40M | $122.97M | $83.36M |
| Cash and equivalents | $219.18M | $209.61M | $96.78M | $158.03M | $112.81M | $66.39M | $48.43M | $33.61M |
| Total liabilities | $172.85M | $181.68M | $177.98M | $170.77M | $112.76M | $103.52M | $137.78M | $37.81M |
| Short-term debt | $2.11M | $2.21M | $2.15M | $1.75M | $642.00K | $970.00K | $1.96M | N/A |
| Shareholder equity | $950.84M | $1.08B | $901.40M | $966.12M | $878.59M | $66.74M | $1.14M | $48.50M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.09B | $1.08B | $1.12B | $1.16B | $1.26B | $1.20B | $1.26B | $1.17B | $1.12B | $1.07B | $1.08B | $1.00B |
| Total liabilities | $163.29M | $167.78M | $172.85M | $177.73M | $161.58M | $178.85M | $181.68M | $141.04M | $157.32M | $159.88M | $177.98M | $136.03M |
| Cash and equivalents | $218.61M | $273.60M | $219.18M | $64.84M | $169.25M | $137.26M | $209.61M | $165.27M | $184.25M | $111.44M | $96.78M | $123.09M |
| Shareholder equity | $928.48M | $916.07M | $950.84M | $979.30M | $1.10B | $1.03B | $1.08B | $1.03B | $961.20M | $913.58M | $901.40M | $864.61M |
Cash Flow
In the fiscal year ended Mar 2026, free cash flow was 97.3% of operating cash flow. Share repurchases came to 135.9% of it.
Annual
| Line item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $326.46M | $273.26M | $184.10M | $179.60M | $126.58M | $82.97M | $26.20M | $15.31M |
| Capital expenditures | $8.90M | $6.53M | $5.80M | $6.18M | $5.70M | $4.61M | $4.24M | $1.19M |
| Free cash flow | $317.56M | $266.74M | $178.29M | $173.42M | $120.88M | $78.36M | $21.95M | $14.12M |
| Share repurchases | $431.65M | $120.29M | $280.72M | $85.32M | $6.68M | $3.49M | $0 | N/A |
| Investing cash flow | $147.17M | -$29.30M | $31.19M | -$59.92M | -$640.57M | -$70.42M | -$13.10M | -$9.07M |
| Financing cash flow | -$464.06M | -$131.14M | -$276.52M | -$74.46M | $560.41M | $5.41M | $1.72M | $985.00K |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $93.28M | $41.99M | $109.52M | $60.89M | $93.94M | $62.10M | $98.49M | $65.19M | $68.35M | $41.24M | $63.94M | $50.05M |
| Capital expenditures | $1.95M | $2.38M | $2.25M | $2.31M | $2.37M | $1.97M | $1.51M | $1.77M | $1.54M | $1.70M | $1.63M | $1.32M |
| Free cash flow | $91.33M | $39.60M | $107.27M | $58.58M | $91.58M | $60.13M | $96.98M | $63.42M | $66.80M | $39.54M | $62.31M | $48.73M |
Frequently Asked Questions About DOCS
What is Doximity's annual revenue?
Doximity reported revenue of $644.86M for the fiscal year ended Mar 31, 2026.
How fast is Doximity's revenue growing?
Revenue was up 13.1% for the fiscal year ended Mar 31, 2026 compared with the year before. The compound annual revenue growth rate over 3 years was 15.5%.
Is Doximity profitable?
Yes. Doximity reported net income of $196.05M for the fiscal year ended Mar 31, 2026, with a net margin of 30.4%.
How much free cash flow does DOCS generate?
For the fiscal year ended Mar 31, 2026, operating cash flow of $326.46M minus capital expenditures of $8.90M produced free cash flow of $317.56M.
How much debt does Doximity have?
The balance sheet dated Mar 31, 2026 reported short-term debt of $2.11M and cash and equivalents of $219.18M.
DOCS pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts